icon-folder.gif   Conference Reports for NATAP  
 
 

16thEuro

Back grey_arrow_rt.gif
 
 
 
BESIDE - HIGH PREVALENCE OF COMORBIDITIES AND CONCOMITANT MEDICATION IN HIV-INFECTED PATIENTS IN GERMANY CARRIES A HIGH POTENTIAL FOR DRUG-DRUG INTERACTIONS WITH ANTIRETROVIRAL THERAPY
 
 
  " only 8.9% of patients aged ≥ 60 years did not suffer from any comorbidities and as many as 44.6% had ≥ 4 comorbidities. Overall, 19.9% of patients suffered from 4 or more non-AIDS associated comorbidities"....31.4% 50-59 years old had 4 or more comorbidities and 14% 40-49 had 4 or more comorbidities.....44% over 60 were taking 4 or more comedications and another 13% adding up to 57% taking 3 or more......."Only 1.5% of patients used comedications, which according to the Liverpool HIV Drug Interactions Database were formally contraindicated with their respective ART regimens: mainly use of proton pump inhibitors in combination with Rilpivirin-containing ART. However, 40.8% took concomitant medications with a potential for drug-drug-interactions that requires closer monitoring or dose adjustments (see Figure 7)."
 
Reported by Jules Levin
EACS Conference 2017, Milan, Italy, October 25-27, 2017
 
B. Funke1, S. Esser2, H.-J. Stellbrink3, C. D. Spinner4, K. Wursthorn5, V. Witte1 1MSD Sharp & Dohme GmbH, Medical Affairs, Haar, Germany, 2University Hospital Essen, University of Duisburg-Essen, Clinic for Dermatology, Essen, Germany, 3Infectiology Center Hamburg (ICH), Hamburg, Germany, 4University Hospital Klinikum rechts der Isar, Department of Medicine II, Munich, Germany, 5IFi Institute for Interdisciplinary Medicine, Asklepios Clinic St. Georg, Hamburg, Germany

1213171

1213172

1213173

1213174

1213175

1213176

1213177

1213178